Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 12.04 -2.19% -0.27
IRWD closed down 2.84 percent on Friday, December 7, 2018, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IRWD trend table...

Date Alert Name Type % Chg
Dec 7 Fell Below 20 DMA Bearish -2.19%
Dec 7 180 Bearish Setup Bearish Swing Setup -2.19%
Dec 7 Down 3 Days in a Row Weakness -2.19%
Dec 7 Down 4 Days in a Row Weakness -2.19%
Dec 6 20 DMA Support Bullish -4.97%
Dec 6 Hammer Candlestick Bullish -4.97%
Dec 6 Down 3 Days in a Row Weakness -4.97%
Dec 4 Overbought Stochastic Strength -5.35%
Dec 3 Stochastic Sell Signal Bearish -12.75%
Dec 3 Overbought Stochastic Strength -12.75%

Older signals for IRWD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Is IRWD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.2
52 Week Low 11.02
Average Volume 1,515,792
200-Day Moving Average 16.9889
50-Day Moving Average 14.796
20-Day Moving Average 12.5
10-Day Moving Average 13.225
Average True Range 0.7722
ADX 25.58
+DI 16.9533
-DI 27.677
Chandelier Exit (Long, 3 ATRs ) 11.8534
Chandelier Exit (Short, 3 ATRs ) 13.3366
Upper Bollinger Band 14.2152
Lower Bollinger Band 10.7848
Percent B (%b) 0.44
BandWidth 27.4432
MACD Line -0.3873
MACD Signal Line -0.5472
MACD Histogram 0.16
Fundamentals Value
Market Cap 1.84 Billion
Num Shares 150 Million
EPS -0.98
Price-to-Earnings (P/E) Ratio -12.56
Price-to-Sales 8.05
Price-to-Book 441.52
PEG Ratio -0.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.17
Resistance 3 (R3) 13.22 12.99 13.02
Resistance 2 (R2) 12.99 12.77 12.96 12.97
Resistance 1 (R1) 12.65 12.64 12.54 12.60 12.93
Pivot Point 12.42 12.42 12.36 12.39 12.42
Support 1 (S1) 12.08 12.20 11.97 12.03 11.69
Support 2 (S2) 11.85 12.07 11.82 11.65
Support 3 (S3) 11.51 11.85 11.60
Support 4 (S4) 11.46